Member Info for Retireby40

Agreed and apologies, I was posting about on another PLC.

DVRG is funded for the accelerated growth expected.

I reckon the vast majority fall beforehand and the vast, vast majority of the AiM fall beforehand.

The best hope of a raise without leaks is if the co has agreed with a handful of IIs to take the shares so it’s announced and they’re taken up before market opens and maybe have a small number for retail investors.

Look at most recent raises on the AiM and I’d say 90% have falls in the days leading up to the RNS.

Anyway, onwards and upwards here!

The results validated Labskin’s ability to provide access to real-world clones of the human skin microbiome, while removing the risk of transmission of the virus to human volunteers. For the first time, users will potentially be able to safely, rapidly and economically test their products, ingredients, treatments and therapies on SARS-CoV-2 and possibly other dangerous viruses/pathogens in real-world environments, following which labelling authorisation could be formally granted.
Extending the Study
The next stage of the investigation will examine the viability of the coronavirus when transferred as full particles from plastic and metal surfaces to a laboratory grown human skin model and the potential risk for infection through the skin itself. It will also further investigate the ability of SARS-CoV-2 to activate innate immune response, its reproductive capability and the duration over which it remains viable and infectious.
The wealth of laboratory reference data generated, potentially supported by DeepVerge’s AI and analytic capabilities, is expected to assist the Group’s gaining of a greater understanding of process and means by which coronavirus is able to so efficiently spread across the globe.

It has already demonstrated an ability to leapfrog giant corporations with its development of user-friendly, real-time COVID-19 detection and alert systems (such as Microtox BT and Microtox PD), identifying products that hold potential to become embedded within the daily routine of global populations desperate to return to some sort of ‘normality’. Indeed, DeepVerge’s ability to adequately service the overwhelming international demand it prospectively faces may become the most significant challenge going forward as it seeks to satisfy the potential being presented across its expanding range of unique, high-margin opportunities.

https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/5c7515f0-fc89-4652-82eb-e6612e2c668e/DeepVergeplc_Research_Update_27_November_2020__FINAL_BGv2.pdf

I muddled some of the pasting so best to read in the right order above

The results validated Labskin’s ability to provide access to real-world clones of the human skin microbiome, while removing the risk of transmission of the virus to human volunteers. For the first time, users will potentially be able to safely, rapidly and economically test their products, ingredients, treatments and therapies on SARS-CoV-2 and possibly other dangerous viruses/pathogens in real-world environments, following which labelling authorisation could be formally granted.
Extending the Study
The next stage of the investigation will examine the viability of the coronavirus when transferred as full particles from plastic and metal surfaces to a laboratory grown human skin model and the potential risk for infection through the skin itself. It will also further investigate the ability of SARS-CoV-2 to activate innate immune response, its reproductive capability and the duration over which it remains viable and infectious.
The wealth of laboratory reference data generated, potentially supported by DeepVerge’s AI and analytic capabilities, is expected to assist the Group’s gaining of a greater understanding of process and means by which coronavirus is able to so efficiently spread across the globe.

Today’s news further highlights DeepVerge’s ability to create value through the timely utilisation of its different skillsets, technologies and international reach, along with management teams that are ‘switched on’ to the prospective long-term opportunity offered through the ongoing health crisis. It has already demonstrated an ability to leapfrog giant corporations with its development of user-friendly, real-time COVID-19 detection and alert systems (such as Microtox BT and Microtox PD), identifying products that hold potential to become embedded within the daily routine of global populations desperate to return to some sort of ‘normality’. Indeed, DeepVerge’s ability to adequately service the overwhelming international demand it prospectively faces may become the most significant challenge going forward as it seeks to satisfy the potential being presented across its expanding range of unique, high-margin opportunities.

DeepVerge plc
Marketing Communication Your Capital is at Risk
DeepVerge has announced breakthrough interim analysis that demonstrates its ability to host the SARS-CoV-2 virus on Labskin-cloned human skin microbiome. This is highly significant in the respect that to date society has been forced to depend on anecdotal or theoretical evidence (from the World Health Organization (‘the WHO’) and various health agencies) to determine how infectious skin is, as humans touch different surfaces and each other. The body of research, protocols and methods now created on Labskin while utilising the real coronavirus, offers formal confirmation and sets necessary standards for oversight testing across a broad range of sanitisers, skin and health care products. The study is now being extended to further investigate behaviours of COVID-19 on skin and enable testing on anti-viral and dental products. Assuming its successful completion, this could rapidly and economically provide scientific evidence that formally backs-up any product claims to kill or address risk of transmission of the virus (or its mutations) without first having to expose human volunteers to it through clinical trials. Given the anticipated post-Pandemic focus on such claims across a multitude of personal and household products, together with strict governmental oversight of all-such related labelling, DeepVerge appears to have once again utilised its unique skillset and technological abilities to identify and prospectively satisfy a long-term, high margin opportunity within mass markets desperate for reassurance that they can return to some form of ‘normality’.
Real-world clones of the human skin microbiome
Labskin scientists, in partnership with the University of Aberdeen through which they gain access to a SARS-CoV-2 virus Category 3 laboratory, have successfully populated and maintained the SARS-CoV-2 virus on skin models upon which various household chemicals, anti-viral, skin and health care products etc, can be applied. Through this the effect on the microbiome itself, as well as the product’s efficacy at killing the virus over different periods of time, can be tested. So far, the study has specifically investigated the virus’ transmissibility from surfaces to airways by measuring its viability when recovered from surface(s) to skin and skin to skin. It also examined what the application of different sanitisers to the skin actually does to COVID-19, along with reduction of titre and/or virulence. Beyond this, it also reviewed ability of the virus to activate innate immune response on human living tissue (using the Labskin model) and the period it can survive there.

Usually the share price falls ahead of a placing but it went up nearly 15% in the 2 weeks beforehand and was only a 5.9% discount on the price the day before which was the 12 month high. No leaks and superb management. Clearly most uptake from US investors hence announced yesterday at 5pm and closed this morning.

Wrong BB, apologies. On app so not sure re delete.

Anyway, more great news here and given we know we are working with Unilever in Liverpool I wonder how many of their products we will be working on? Not just Unilever but I imagine many existing and new clients will be doing so.
Remember the recently launched remote trials I imagine will grow very quickly in this embryonic phase and we will be doing very well from that stream come 2021 and beyond.

Usually the share price falls ahead of a placing but it went up nearly 15% in the 2 weeks beforehand and was only a 5.9% discount on the price the day before which was the 12 month high. No leaks and superb management. Clearly most uptake from US investors hence announced yesterday at 5pm and closed this morning.

Yes you are as per the RNS. May take a few days for your platform to update their corporate actions section.

Hats off the to CEO who made a lot Of changes on arrival.
The raises illustrate how well he’s done. £15m raises July last year at 15p and now a £23m raise at 40p when we only got there last week and were at 35p 3 weeks before. Amazing and clearly a lot of US interest. We only burnt £1.1m cash in 2 months (July 10-Aug 19 below) and had £13.3m as end of August so sill have a lot of runway. A very good time to raise money and we should have some £35m cash to take us to massive growth, profitability but I imagine a takeover beforehand.
-- Revenue increased by 109% to GBP897k (30 June 2019 GBP429k), despite the impact of Covid-19, as the Group continues to deliver against its strategy
-- Cash and cash equivalents of GBP14.4m (30 June 2019 GBP9.2m), up 57% following the 2019 fundraise, net of trading losses. Gross cash balance at end August 2020 is GBP13.3m.
-- Cash consumption significantly reduced to GBP4.5m (30 June 2019 GBP5.9m), down 24%, through proactive cost management while the volume of activity increased

Dr Cardente highlighted the Deepverge Microtox PD technology in particular.
The mechanism of detection of SARS-Cov-2 with the Microtox Optofluidic monitor
Microfluidics, Photonics and AI
Microtox PD was explained in depth in its use of AI and Machine learning; the platforms merging of microfluidics, photonics and AI; and its potential to detect a range of bad actors in water in real time. The systems history of development from an E. coli detection system developed with the Environment Protection Agency, Ireland to its application today in Covid detection was also highlighted.
As Deepverge continues to work with the scientific community across the world, it will continue listening and learning from the science and continuously work to develop surveillance systems for Covid-19 and other pathogens, viruses and bad actors that pollute the world’s water, not only detecting outbreaks, but also – and ultimately – signalling the size of a cluster to help authorities take appropriate and weighted remedial action.

Deepverge Featured at Italian Government Conference
Deepverge was honoured to be featured today at the Italian Government conference on Covid-19 and the environment.
The web conference was headed by ISPRA (the equivalent of the Italian Environmental Protection Agency), with almost 200 prominent researchers and scientists in the field of Ecotoxicology attending. It was coordinated by prominent scientists Dr. Raffaela Cardente and Prof. Francesco Regoli. The conference was held to discuss the latest developments, research and technologies in Ecotoxicology as well as the impact of Covid-19 on the environment.
The main speakers were Dr. Raffaela Cardente (Ecotox), Prof. Francesco Regoli (Polytechnic University Of Marche). The conference was headed by Dr. Alessandro Bratti Director Of Ispra (Superior Institute Of Research And Environment Protection).
Comparing and Understanding the Data
During this Covid-19 pandemic many studies, observations, and scientific advancements have been made. The intention of the conference was to understand and compare data and findings by the Italian and international community of Ecotoxicologists.
After a brief introduction by Dr Alessandro Bratti (ISPRA) that praised the efforts of the scientific community during these times, he highlighted the importance of studying and finding solutions to counter the impact of new pollutants (e.g. increased use of disposable masks, byproducts of sanitisers), waste and pathogens that are directly related to the pandemic. Many of these have greatly affected the environment on a global scale. He stressed the impact that Covid-19 has had on increasing water pollution and the importance of focused studies and research to preserve that specific ecosystem.
The Increasing Risks of Pandemic
Prof. Pergoli explained how climate change and anthropogenic pressures have increased the risks of pandemic. He further explained it is fundamental that the scientific community should endeavour to predict and mitigate environmental pollution on a long-term basis. He warned of the direct effects of environmental issues on marine organisms and the marine ecosystem. Sharing data on different studies conducted on that subject such as new pollutants (e.g. Hypoxia, Salinity, Global Warming, Eutophication, Ocean Acidification and Anthropogenic pollution) he finally stressed the importance of using new biological models, new analytical technologies, bioinformatic and elaboration procedures for improved new predictive possibilities.
Dr Raffaela Cardente presented her study on Covid-19 and the environment. She focused on the correlation between pandemics and environmental conditions and methods of direct and indirect research to collect data on the impact of pandemics.
Dr Cardente highlighted the Deepverge Microtox PD technology in particular.
The mechanism of detection of SARS-Cov-2 with the Microtox Optofluidic monitor
Microfluidics, Photonics and AI
Microtox PD was explained in depth in its use of A

It’s PEEL and CFEP always at the top of both sides of the bid/offer.

I hope we get an RNS ahead of next week’s presentation whether it be reach or not as always good to go back readily and take the content in again.

I’m sitting on a number of shares I’ll keep for a good while. Other holdings I’ll diminish but these boys are staying put for a good while.

Paul, I see your point. The acquisition I believe will be recorded on the balance sheet this year.

Paulcon, how would MWG losses alter DVRG’s turnover? They are very different things!!!

£4m is for DVRG excluding MWG revenue so including it I was guess it would be nearer to £7m than £6m as H2 should have been a lot better judging by the RNSs.

I would also hope MWG with its increase in H2 revenue might BE H2 to both sides not burning any cash in H2 and I would expect with £3m revenue H2 DVRG would generate some cash.

Really looking forward to an ops update, it’d be great to know what we are starting 2021 with revenue-wise for Labskin alone with 10 framework agreements it could be near to £2m!

Also how is AMBC doing, we know they’ve been busy in India and South Korea, how are the other partners doing. Pipeline any good?

Anyway, am really looking forward to next week. I hope the share price doesn’t go up to much before but increases afterwards.

51
PaulCon, touché! Fair point although having just reaffirmed £4m with a little over a month to see out suggesting it’ll be blown out of the water is even more OTT than my suggestion.

For me the saying revenue for show and profit for dough resonates. I’d rather make profit with a smaller revenue than a higher revenue and burning cash. Sounds basic but so many can lose sight of this. That’s why collaborating, using existing tech and modifying etc are key to keeping costs down and ensuring money can be made. A larger cake but a smaller slice.

The fact we were asked (through our local distribution partners) so present at a man Italian gov conference is telling. Who would not want the ability to detect Covid and other targets real-time? Surely this will be the gold standard and once one Gov deploys it or even regulates for it they all will.

Exciting times.

PaulCon, touché! Fair point although having just reaffirmed £4m with a little over a month to see out suggesting it’ll be blown out of the water is even more OTT than my suggestion.

For me the saying revenue for show and profit for dough resonates. I’d rather make profit with a smaller revenue than a higher revenue and burning cash. Sounds basic but so many can lose sight of this. That’s why collaborating, using existing tech and modifying etc are key to keeping costs down and ensuring money can be made. A larger cake but a smaller slice.

The fact we were asked (through our local distribution partners) so present at a gov conference is telling. Who would not want the ability to detect Covid and other targets real-time? Surely this will be the gold standard and once one Gov deploys it or even regulates for it they all will.

Exciting times.

I was replying to dafad’s post - I have a sneaky suspicion that the GPB 4m will be blown out the water.

My bet is we will do £4m which is superb and suggesting it’ll be smashed it rampy which isn’t needed or healthy as from £1m 2019 and £1m H1 2020 to £3m H2 2020 and £4m FY speaks for itself.

Real-time water detection was already in motion for 3 years and ecoli proved it a year ago so adapting to new viruses was inevitable and the timing for Covid works. Post Covid it will be used and given clean water scarcity is only going to get worse we are in a great space.
The breathalyser will also work on 40 or so targets and could also be massive so great that we’ll get news on the testing early 2021. Even without that the potential for labskin, AI, water monitoring and AMBC are massive. We have cash and access to debt so can fund growth. A profitable 2021 i guess anyway. I also guess including MWG the Group revenue will be nearer to £13m than £10m.

Regardless we are funded into 2021 and I expect 2021 to be profitable.

Why not say £4m will be exceeded by circa X % then?

£3m H2 so £4m FY is superb so saying it’ll be blown out of the water is rampy nonsense.

I reckon next year will be massive and remember with £3m in H2 it’s gonna be a profitable half and 2021 will be massive.

Didn’t Tom W short NCYT at £1. Ouch.